Indalpine

CHEMBL276520 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
228.3 g/mol
LogP
3.3
Phase
4

This selective serotonin reuptake inhibitor (SSRI) was one of the earliest drugs in its class, developed in France to treat depression by increasing serotonin levels in the brain. It was withdrawn from clinical use due to rare but serious blood cell disorders.

Berat Molekul

228,3300 g/mol

LogP

3,30

TPSA

27,80 Ų

Lipinski RO5

Lulus

Mekanisme Kerja

Selectively inhibits the serotonin reuptake transporter (SERT) at presynaptic neurons, increasing serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is associated with antidepressant and anxiolytic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Selectively inhibits the serotonin reuptake transporter (SERT) at presynaptic neurons, increasing serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is associated with antidepressant and anxiolytic effects.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

c1ccc2c(CCC3CCNCC3)c[nH]c2c1

InChI

InChI=1S/C15H20N2/c1-2-4-15-14(3-1)13(11-17-15)6-5-12-7-9-16-10-8-12/h1-4,11-12,16-17H,5-10H2

Molecular Formula

C15H20N2

HBD / HBA

2 / 1

Ikatan yang Dapat Dirotasi

3

Atom Berat

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This selective serotonin reuptake inhibitor (SSRI) was one of the earliest drugs in its class, developed in France to treat depression by increasing serotonin levels in the brain. It was withdrawn from clinical use due to rare but serious blood cell disorders.

Selectively inhibits the serotonin reuptake transporter (SERT) at presynaptic neurons, increasing serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is associated with antidepressant and anxiolytic effects.

Yes, Indalpine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL276520. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 44668. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.